Gilead Sciences Inc
GILD XNAS
$166.89
-0.68 (-0.41%)
▼
15-min delayed
Open
$164.11
High
$169.06
Low
$164.00
Volume
5.82M
Market Cap
$207.00B
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
TickerDaily Coverage
Stock Market Today, October 11, 2026: This Week's Earnings Calendar and Trading Setups
Market News
David Brooks · Oct 12, 2026
The trading week of October 19-23, 2026 arrives heavy with earnings firepower. Tesla, Netflix, and...
Healthcare Stocks This Week: XLV Outpaces S&P 500 Amid Rate Pause Optimism (Oct 5–9, 2026)
Market News
David Brooks · Oct 9, 2026
The healthcare sector navigated a volatile week with conviction, as the XLV ETF gained 2.8% from...
Healthcare Stocks This Week: XLV Gains 2.1% as UNH, LLY Lead Sector Rally (Aug 3–7, 2026)
Market News
David Brooks · Aug 7, 2026
The healthcare sector finished the week with solid momentum, as the Health Care Select Sector SPDR...
Stock Market This Week: Earnings Preview for August 3-7, 2026 — Disney, Eli Lilly, Caterpillar Lead Earnings Deluge
Market News
David Brooks · Jul 27, 2026
The stock market enters earnings season's heaviest week with mega-cap reports from Disney, Eli...
Healthcare Stocks This Week: XLV Outperforms on Rate Cut Bets — Weekly Roundup (Jun 29 – Jul 3, 2026)
Market News
David Brooks · Jul 3, 2026
The healthcare sector capped a record-breaking first half with a strong week as XLV rallied on...
View All Coverage →
Get GILD Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Gilead Sciences Inc.
Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.